Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study

View ORCID ProfileLan Chen, Zhen-Yu Zhang, Jian-Guo Fu, Zhi-Peng Feng, Su-Zhen Zhang, Qiu-Ying Han, Xiao-Bin Zhang, Xiong Xiao, Hui-Min Chen, Li-Long Liu, Xian-Li Chen, Yu-Pei Lan, De-Jin Zhong, Lan Hu, Jun-Hui Wang, Xing-Hua Yu, Dan-Yang She, Yong-Hong Zhu, Zhen-Yu Yin
doi: https://doi.org/10.1101/2020.06.19.20136093
Lan Chen
1Zhongshan Hospital, Xiamen University, Xiamen, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lan Chen
Zhen-Yu Zhang
1Zhongshan Hospital, Xiamen University, Xiamen, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jian-Guo Fu
1Zhongshan Hospital, Xiamen University, Xiamen, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhi-Peng Feng
1Zhongshan Hospital, Xiamen University, Xiamen, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Su-Zhen Zhang
1Zhongshan Hospital, Xiamen University, Xiamen, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qiu-Ying Han
1Zhongshan Hospital, Xiamen University, Xiamen, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiao-Bin Zhang
1Zhongshan Hospital, Xiamen University, Xiamen, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiong Xiao
2Department of Respiratory, Xiamen Branch of Zhongshan Hospital Affiliated to Fudan University, Xiamen, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hui-Min Chen
3Department of Intensive Care Unit, Xiamen Third Hospital, Xiamen, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Li-Long Liu
4Department of Infectious Disease, Hongai Hospital, Xiamen, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xian-Li Chen
5Department of Infectious Disease, Xiang’an Hospital Affiliated to Xiamen University, Xiamen, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yu-Pei Lan
6General Office, Xiamen Haicang Hospital, Xiamen, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
De-Jin Zhong
7Department of Gastroenterology, Xiamen Changgen Hospital, Xiamen, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lan Hu
8Optics Valley Branch of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, Wuhan, Hubei, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jun-Hui Wang
8Optics Valley Branch of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, Wuhan, Hubei, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xing-Hua Yu
1Zhongshan Hospital, Xiamen University, Xiamen, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dan-Yang She
9Department of Pulmonary and Critical Care Medicine, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: yinzy@xmu.edu.cn dysheh@163.com yonghong.zhu.yz2@roche.com
Yong-Hong Zhu
10Early Clinical Development of Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center, Shanghai 201203, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: yinzy@xmu.edu.cn dysheh@163.com yonghong.zhu.yz2@roche.com
Zhen-Yu Yin
1Zhongshan Hospital, Xiamen University, Xiamen, Fujian, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: yinzy@xmu.edu.cn dysheh@163.com yonghong.zhu.yz2@roche.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

The outbreak of novel coronavirus disease 2019 (COVID-19) has become a pandemic. Drug repurposing may represent a rapid way to fill the urgent need for effective treatment. We evaluated the clinical utility of chloroquine and hydroxychloroquine in treating COVID-19.

Forty-eight patients with moderate COVID-19 were randomized to oral treatment with chloroquine (1000 mg QD on Day 1, then 500 mg QD for 9 days; n=18), hydroxychloroquine (200 mg BID for 10 days; n=18), or control treatment (n=12).

Adverse events were mild, except for one case of Grade 2 ALT elevation. Adverse events were more commonly observed in the chloroquine group (44.44%) and the hydroxychloroquine group (50.00%) than in the control group (16.67%). The chloroquine group achieved shorter time to clinical recovery (TTCR) than the control group (P=0.019). There was a trend toward reduced TTCR in the hydroxychloroquine group (P=0.049). The time to reach viral RNA negativity was significantly faster in the chloroquine group and the hydroxychloroquine group than in the control group (P=0.006 and P=0.010, respectively). The median numbers of days to reach RNA negativity in the chloroquine, hydroxychloroquine, and control groups was 2.5 (IQR: 2.0-3.8) days, 2.0 (IQR: 2.0-3.5) days, and 7.0 (IQR: 3.0-10.0) days, respectively. The chloroquine and hydroxychloroquine groups also showed trends toward improvement in the duration of hospitalization and findings on lung computerized tomography (CT). This study provides evidence that (hydroxy)chloroquine may be used effectively in treating moderate COVID-19 and supports larger trials.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

ChiCTR2000030054

Clinical Protocols

http://www.chictr.org.cn/edit.aspx?pid=49869&htm=4

Funding Statement

This study was funded by the Medical and Health Key project of Xiamen (3502Z20191106), which is a project of the Xiamen Science and Technology Bureau (3502Z20194016).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Xiamen zhongshan hospital

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • CONFLICT OF INTEREST The authors declare no conflict of interest regarding the contents of this article

  • FUNDING This study was funded by the Medical and Health Key project of Xiamen (3502Z20191106), which is a project of the Xiamen Science and Technology Bureau (3502Z20194016)

Data Availability

The corresponding author are responsible for interpreting all data referred to in the manuscript E-mail: yinzy@xmu.edu.cn

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted June 22, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study
Lan Chen, Zhen-Yu Zhang, Jian-Guo Fu, Zhi-Peng Feng, Su-Zhen Zhang, Qiu-Ying Han, Xiao-Bin Zhang, Xiong Xiao, Hui-Min Chen, Li-Long Liu, Xian-Li Chen, Yu-Pei Lan, De-Jin Zhong, Lan Hu, Jun-Hui Wang, Xing-Hua Yu, Dan-Yang She, Yong-Hong Zhu, Zhen-Yu Yin
medRxiv 2020.06.19.20136093; doi: https://doi.org/10.1101/2020.06.19.20136093
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study
Lan Chen, Zhen-Yu Zhang, Jian-Guo Fu, Zhi-Peng Feng, Su-Zhen Zhang, Qiu-Ying Han, Xiao-Bin Zhang, Xiong Xiao, Hui-Min Chen, Li-Long Liu, Xian-Li Chen, Yu-Pei Lan, De-Jin Zhong, Lan Hu, Jun-Hui Wang, Xing-Hua Yu, Dan-Yang She, Yong-Hong Zhu, Zhen-Yu Yin
medRxiv 2020.06.19.20136093; doi: https://doi.org/10.1101/2020.06.19.20136093

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (76)
  • Allergy and Immunology (194)
  • Anesthesia (54)
  • Cardiovascular Medicine (488)
  • Dentistry and Oral Medicine (89)
  • Dermatology (56)
  • Emergency Medicine (168)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (211)
  • Epidemiology (5661)
  • Forensic Medicine (3)
  • Gastroenterology (215)
  • Genetic and Genomic Medicine (856)
  • Geriatric Medicine (88)
  • Health Economics (229)
  • Health Informatics (759)
  • Health Policy (388)
  • Health Systems and Quality Improvement (250)
  • Hematology (105)
  • HIV/AIDS (181)
  • Infectious Diseases (except HIV/AIDS) (6455)
  • Intensive Care and Critical Care Medicine (388)
  • Medical Education (116)
  • Medical Ethics (28)
  • Nephrology (90)
  • Neurology (845)
  • Nursing (44)
  • Nutrition (141)
  • Obstetrics and Gynecology (161)
  • Occupational and Environmental Health (258)
  • Oncology (514)
  • Ophthalmology (162)
  • Orthopedics (44)
  • Otolaryngology (105)
  • Pain Medicine (47)
  • Palliative Medicine (21)
  • Pathology (149)
  • Pediatrics (248)
  • Pharmacology and Therapeutics (146)
  • Primary Care Research (113)
  • Psychiatry and Clinical Psychology (959)
  • Public and Global Health (2222)
  • Radiology and Imaging (375)
  • Rehabilitation Medicine and Physical Therapy (174)
  • Respiratory Medicine (311)
  • Rheumatology (109)
  • Sexual and Reproductive Health (80)
  • Sports Medicine (82)
  • Surgery (118)
  • Toxicology (25)
  • Transplantation (34)
  • Urology (42)